ReviewInternational journal of molecular medicine2018
β-glucans and cholesterol (Review).
Review in International journal of molecular medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 107 citations in OpenAlex.
- Trial
- Trial
- Natural Bioactive Compounds Targeting Gut Barrier Integrity and Metabolic Endotoxemia in Cardiometabolic Disease: Mechanistic Insights and Translational Perspectives.Molecules (Basel, Switzerland) · 2026Review
- A comparative study of the productive and physiological effect of beta-glucan and mixture of vitamin C with zinc in heat-stressed Awassi sheep.Open veterinary journal · 2026Article
- Differential Safety and Lipid Control Efficacy of β-1,3/1,6-Glucan Oligosaccharides and Polysaccharides Derived FromFood science & nutrition · 2026Article
- Effect of a homemade diet compared to a commercial diet on glycaemic variability and glycaemic control assessed by continuous glucose monitoring system in diabetic dogs: a randomised crossover study.The Journal of small animal practice · 2026Article
- Gut microbiota and uveitis: exploring novel mechanisms of inflammatory ocular diseases via the gut-eye axis.Frontiers in microbiology · 2026Review
- Impact of Drying Methods on β-Glucan Retention and Lipid Stability in Oyster Mushroom (Molecules (Basel, Switzerland) · 2025Article
- Multidimensional nutritional assessment of goats fed Pleurotus pulmonarius-treated empty fruit bunch.Tropical animal health and production · 2025Article
- Pichia kudriavzevii yeast cell wall as a novel source of β-glucan: Extraction, characterization, and prebiotic functionality.Folia microbiologica · 2025Article
- Pleurotus Mushrooms in Nutrition and Health: Clinical and Preclinical Insights for Nutraceutical Development.Comprehensive reviews in food science and food safety · 2025Review
- Fungal Metabolomics: A Comprehensive Approach to Understanding Pathogenesis in Humans and Identifying Potential Therapeutics.Journal of fungi (Basel, Switzerland) · 2025Review
- Nutritional Factors Related to Canine Gallbladder Diseases-A Scoping Review.Veterinary sciences · 2024Review
- The Significant Therapeutic Effects of Chinese Scorpion: Modern Scientific Exploration of Ion Channels.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Harnessing Prebiotics to Improve Type 2 Diabetes Outcomes.Nutrients · 2024Review
- Review
- The Effects of Lentinan on the Hematological and Immune Indices of Dairy Cows.Animals : an open access journal from MDPI · 2024Article
- Mushroom consumption and cardiometabolic health outcomes in the general population: a systematic review.Nutrition research and practice · 2024Review
- The treasured giants: a current overview on agricultural, nutritional, bioactive, and economic potential ofFrontiers in cellular and infection microbiology · 2024Review
- The Role of Carbohydrate Intake on the Gut Microbiome: A Weight of Evidence Systematic Review.Microorganisms · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypercholesterolemia is one of primary risk factors of cardiovascular disease, together with metabolic syndrome, hypertension and diabetes. Although progress has been made, the search for novel methods of preventing and treating dyslipidemia is ongoing and current therapies for cardiovascular disease induce various side effects. β‑glucans are linear unbranched polysaccharides found in various natural sources, such as mushrooms. Due to their structure they are able to interact with innate immunity receptors, however they also act as dietary fibers in the digestive tract. As there are two forms of β‑glucans, insoluble and soluble forms, they are able to interact with lipids and biliary salts in the bowel and consequently reduce cholesterol levels. Therefore, they may be developed as a suitable therapeutic option to treat patients with dyslipidemia, as they are natural molecules that do not induce any significant side effects. The current review discusses the evidence supporting the effects of β‑glucans on cholesterol levels.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.